Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06787339 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Capecitabine in Low Risk Triple Negative Breast Cancer

Name: Capecitabine in Low Risk Triple Negative Breast Cancer — clinical trial record (NCT06787339)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Calorite

StatusRecruiting

PhasePhase 2

SponsorFudan University

Started2025-01-20

View on ClinicalTrials.gov ↗

Amendment history

2026-09-29

Recruitment opened

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year.

Trial Details

NCT Number	NCT06787339
Lead Sponsor	Fudan University
Conditions	Breast Cancer
Enrollment	198 participants
Start Date	2025-01-20
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-28